News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
14,796 Results
Type
Article (834)
Company Profile (18)
Press Release (13943)
Multimedia
Podcasts (2)
Webinars (2)
Section
Business (4632)
Career Advice (17)
Deals (675)
Drug Delivery (2)
Drug Development (2523)
Employer Resources (2)
FDA (315)
Job Trends (346)
News (7687)
Policy (426)
Tag
Academia (38)
Accelerated approval (2)
Adcomms (5)
Allergies (6)
Alliances (1246)
ALS (1)
Alzheimer's disease (13)
Antibody-drug conjugate (ADC) (20)
Approvals (312)
Artificial intelligence (9)
Autoimmune disease (9)
Bankruptcy (6)
Best Places to Work (290)
BIOSECURE Act (5)
Biosimilars (4)
Biotechnology (14)
Bladder cancer (1)
Brain cancer (1)
Breast cancer (4)
Cancer (127)
Cardiovascular disease (12)
Career advice (10)
CAR-T (16)
CDC (1)
Cell therapy (56)
Clinical research (2072)
Collaboration (68)
Compensation (34)
Complete response letters (4)
COVID-19 (105)
CRISPR (7)
C-suite (42)
Cystic fibrosis (1)
Data (201)
Diabetes (13)
Diagnostics (42)
Drug discovery (9)
Drug pricing (1)
Earnings (1579)
Editorial (2)
Employer resources (2)
Events (2693)
Executive appointments (51)
FDA (405)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (1)
Funding (52)
Gene editing (12)
Gene therapy (38)
GLP-1 (23)
Government (59)
Guidances (7)
Healthcare (404)
Immunology and inflammation (14)
Immuno-oncology (2)
Indications (2)
Infectious disease (107)
Inflammatory bowel disease (16)
Intellectual property (6)
Interviews (3)
IPO (373)
Job creations (62)
Job search strategy (10)
JPM (2)
Kidney cancer (1)
Labor market (5)
Layoffs (20)
Legal (70)
Liver cancer (2)
Lung cancer (16)
Lymphoma (22)
Machine learning (1)
Management (1)
Manufacturing (30)
MASH (2)
Medical device (131)
Medtech (131)
Mergers & acquisitions (335)
Metabolic disorders (22)
Neurodegenerative disease (9)
Neuroscience (28)
NextGen: Class of 2026 (150)
Non-profit (22)
Now hiring (1)
Obesity (7)
Opinion (1)
Ovarian cancer (4)
Pain (12)
Pancreatic cancer (2)
Parkinson's disease (5)
Patents (14)
Patient recruitment (11)
People (1797)
Pharmacy benefit managers (2)
Phase 1 (876)
Phase 2 (960)
Phase 3 (694)
Pipeline (176)
Policy (14)
Postmarket research (33)
Preclinical (291)
Press Release (2)
Prostate cancer (3)
Psychedelics (1)
Radiopharmaceuticals (2)
Rare diseases (38)
Real estate (115)
Recruiting (1)
Regulatory (435)
Reports (3)
Research institute (64)
Resumes & cover letters (3)
RSV (1)
Schizophrenia (3)
Series A (14)
Series B (5)
Service/supplier (1)
Sickle cell disease (2)
Special edition (2)
Spinal muscular atrophy (1)
Sponsored (2)
Startups (109)
Supply chain (2)
Tariffs (2)
The Weekly (2)
Vaccines (16)
Venture capital (4)
Weight loss (3)
Women's health (1)
Date
Today (4)
Last 7 days (19)
Last 30 days (56)
Last 365 days (914)
2026 (92)
2025 (935)
2024 (1122)
2023 (1347)
2022 (1722)
2021 (1734)
2020 (1332)
2019 (810)
2018 (595)
2017 (728)
2016 (578)
2015 (628)
2014 (431)
2013 (367)
2012 (320)
2011 (322)
2010 (328)
Location
Africa (16)
Asia (1158)
Australia (93)
California (544)
Canada (140)
China (37)
Colorado (3)
Connecticut (9)
Delaware (14)
Europe (1524)
Florida (35)
Georgia (13)
Idaho (1)
Illinois (19)
India (9)
Indiana (4)
Japan (17)
Maine (1)
Maryland (64)
Massachusetts (240)
Michigan (4)
Minnesota (6)
Nevada (1)
New Jersey (80)
New Mexico (1)
New York (45)
North Carolina (18)
Northern California (250)
Ohio (2)
Oklahoma (1)
Pennsylvania (76)
South America (9)
Southern California (194)
Tennessee (2)
Texas (38)
United States (1216)
Utah (7)
Virginia (1)
Washington D.C. (2)
Washington State (17)
Wisconsin (2)
14,796 Results for "axial biotherapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Augurex Life Sciences Granted FDA Breakthrough Designation for SPINEstat®, its First-in-Class Diagnostic Test for Axial Spondyloarthritis
October 28, 2025
·
1 min read
Press Releases
BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis
October 27, 2025
·
26 min read
Press Releases
Filgotinib Shows Positive Topline Results Across Full Spectrum of Axial Spondyloarthritis in OLINGUITO Phase 3 Study
July 28, 2025
·
9 min read
Press Releases
Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa
January 27, 2026
·
5 min read
Press Releases
Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026
January 29, 2026
·
8 min read
Press Releases
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)
January 12, 2026
·
7 min read
Press Releases
BIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis
June 12, 2025
·
24 min read
Press Releases
Augurex Secures Health Canada Approval for SPINEstat™, a First-in-Class Diagnostic Blood Test for Axial Spondyloarthritis
April 16, 2025
·
1 min read
Press Releases
Augurex Secures Health Canada Approval for SPINEstat™, a First-in-Class Diagnostic Blood Test for Axial Spondyloarthritis
April 16, 2025
·
3 min read
BioMidwest
UCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024
UCB announced the first presentation of two-year data from the Phase 3 studies, BE MOBILE 1 and BE MOBILE 2, and the open-label extension, BE MOVING, evaluating BIMZELX, an interleukin -17A and IL-17F inhibitor, in the treatment of active non-radiographic axial spondyloarthritis and ankylosing spondylitis, also known as radiographic axial spondyloarthritis.
June 12, 2024
·
21 min read
1 of 1,480
Next
